Phenaros Pharmaceuticals

About Phenaros Pharmaceuticals

Phenaros utilizes phenomics and AI-driven cell morphological profiling to accelerate drug discovery for rare diseases by automating data collection and experimentation. The company addresses the challenge of limited high-quality data in drug development, enabling faster and more efficient identification of new and repurposed therapeutics.

```xml <problem> Drug discovery for rare diseases is hindered by the limited availability of high-quality data, making it difficult to identify and develop effective therapeutics. Traditional methods of data collection and experimentation are often slow, expensive, and lack the depth of insight needed to understand complex disease mechanisms. </problem> <solution> Phenaros leverages phenomics and artificial intelligence (AI) to accelerate drug discovery for rare diseases through automated cell morphological profiling. The company employs Cell Painting, a phenomics approach, to reveal detailed cellular information, which is then combined with AI modeling for iterative drug discovery. By using state-of-the-art AI to guide decisions and robotics and automation for intelligent experimentation, Phenaros systematically engineers the data used to build its AI system. This data-centric approach enables the company to perform targeted experiments, reducing both the time and cost associated with traditional drug discovery cycles. </solution> <features> - Cell Painting-based phenomics for detailed cellular insights - AI-driven analysis of cell morphology to identify potential drug candidates - Automated data collection and experimentation using robotics - Iterative drug discovery process guided by AI modeling - Systematic engineering of data to optimize AI system performance </features> <target_audience> Phenaros primarily targets pharmaceutical companies, research institutions, and drug development organizations focused on discovering and developing treatments for rare diseases. </target_audience> ```

What does Phenaros Pharmaceuticals do?

Phenaros utilizes phenomics and AI-driven cell morphological profiling to accelerate drug discovery for rare diseases by automating data collection and experimentation. The company addresses the challenge of limited high-quality data in drug development, enabling faster and more efficient identification of new and repurposed therapeutics.

Where is Phenaros Pharmaceuticals located?

Phenaros Pharmaceuticals is based in Stockholm, Sweden.

When was Phenaros Pharmaceuticals founded?

Phenaros Pharmaceuticals was founded in 2024.

Who founded Phenaros Pharmaceuticals?

Phenaros Pharmaceuticals was founded by Jordi Carreras Puigvert and Ola Spjuth.

  • Jordi Carreras Puigvert - CSO/Co-Founder
  • Ola Spjuth - CEO
Location
Stockholm, Sweden
Founded
2024
Employees
8 employees
Looking for specific startups?
Try our free semantic startup search

Phenaros Pharmaceuticals

Score: 99/100
AI-Generated Company Overview (experimental) – could contain errors

Executive Summary

Phenaros utilizes phenomics and AI-driven cell morphological profiling to accelerate drug discovery for rare diseases by automating data collection and experimentation. The company addresses the challenge of limited high-quality data in drug development, enabling faster and more efficient identification of new and repurposed therapeutics.

phenaros.com700+
Founded 2024Stockholm, Sweden

Funding

No funding information available. Click "Fetch funding" to run a targeted funding scan.

Team (5+)

Jordi Carreras Puigvert

CSO/Co-Founder

Ola Spjuth

CEO

Company Description

Problem

Drug discovery for rare diseases is hindered by the limited availability of high-quality data, making it difficult to identify and develop effective therapeutics. Traditional methods of data collection and experimentation are often slow, expensive, and lack the depth of insight needed to understand complex disease mechanisms.

Solution

Phenaros leverages phenomics and artificial intelligence (AI) to accelerate drug discovery for rare diseases through automated cell morphological profiling. The company employs Cell Painting, a phenomics approach, to reveal detailed cellular information, which is then combined with AI modeling for iterative drug discovery. By using state-of-the-art AI to guide decisions and robotics and automation for intelligent experimentation, Phenaros systematically engineers the data used to build its AI system. This data-centric approach enables the company to perform targeted experiments, reducing both the time and cost associated with traditional drug discovery cycles.

Features

Cell Painting-based phenomics for detailed cellular insights

AI-driven analysis of cell morphology to identify potential drug candidates

Automated data collection and experimentation using robotics

Iterative drug discovery process guided by AI modeling

Systematic engineering of data to optimize AI system performance

Target Audience

Phenaros primarily targets pharmaceutical companies, research institutions, and drug development organizations focused on discovering and developing treatments for rare diseases.